Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hagop Kantarjian

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Journal of Clinical Oncology

English

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Journal of Clinical Oncology

English

Down-Regulation of Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Receptor Beta-Chain in BCR-ABL+ Human Leukemic Cells: Association With Loss of Cytokine-Mediated Stat-5 Activation and Protection From Apoptosis After BCR-ABL Inhibition

English

Survival Is Poorer in Patients With Secondary Core Binding Factor Acute Myelogenous Leukemia Compared With De Novo Core Binding Factor Leukemia.

English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

English

Relative Increase in Leukemia-Specific DNA in Peripheral Blood Plasma From Patients With Acute Myeloid Leukemia and Myelodysplasia

English

Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia

English

Clofarabine, a Novel Nucleoside Analog, Is Active in Pediatric Patients With Advanced Leukemia

English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research

Oncology

2004

English

Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Hagop Kantarjian

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Down-Regulation of Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Receptor Beta-Chain in BCR-ABL+ Human Leukemic Cells: Association With Loss of Cytokine-Mediated Stat-5 Activation and Protection From Apoptosis After BCR-ABL Inhibition

Survival Is Poorer in Patients With Secondary Core Binding Factor Acute Myelogenous Leukemia Compared With De Novo Core Binding Factor Leukemia.

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Relative Increase in Leukemia-Specific DNA in Peripheral Blood Plasma From Patients With Acute Myeloid Leukemia and Myelodysplasia

Imatinib Mesylate Therapy May Overcome the Poor Prognostic Significance of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia

Clofarabine, a Novel Nucleoside Analog, Is Active in Pediatric Patients With Advanced Leukemia

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities